Sponsors (2)
The bill centralizes federal agricultural biotechnology leadership to streamline regulation, commercialization, research coordination, and outreach—potentially accelerating adoption and market entry—while raising costs, concentrating decision‑making power that could favor commercialization over stricter safety or transparency, and risking diversion of USDA resources.
Farmers and agricultural producers will have a single USDA point of contact and clearer interagency coordination (USDA, EPA, FDA), making it easier to navigate regulation, labeling, and commercialization of biotech products.
Farmers and rural communities will get better outreach, extension, and education on safe biomanufacturing and synthetic biology tools, increasing access to information and supporting adoption of beneficial technologies.
Scientists and researchers will gain a centralized USDA office to coordinate federal agricultural biotechnology R&D, improving support, collaboration, and prioritization of research efforts.
Taxpayers and other USDA program beneficiaries face higher administrative costs because creating and staffing a new Office increases USDA overhead and may divert funding from existing programs.
Farmers, rural communities, and the environment could face greater risk if centralizing biotech policy within USDA biases regulatory and labeling decisions toward commercialization rather than stricter safety or environmental protections.
Stakeholders and members of the public may have reduced independent scientific review or public input because centralized authority reporting to the Secretary could limit transparency and outside oversight.
Based on analysis of 2 sections of legislative text.
Creates an Office of Biotechnology Policy at USDA to coordinate R&D, outreach, regulation, labeling, commercialization, and interagency/state engagement on biotechnology.
Introduced September 3, 2025 by Alejandro Padilla · Last progress September 3, 2025
Creates an Office of Biotechnology Policy at the U.S. Department of Agriculture to coordinate USDA work on biotechnology, biomanufacturing, synthetic biology, and related emerging technologies. The Office will be led by a Director who reports to the Secretary (or the Secretary’s designee) and will align Department activities on research and development, outreach and education, regulation and labeling, and commercialization and trade. The Office must assist other USDA offices with biotechnology responsibilities, carry out duties assigned by law or the Secretary, lead interagency coordination with agencies such as EPA and FDA, and consult with developers, academics, agricultural producers, and other stakeholders. The bill also preserves the Secretary’s existing authority to implement the new Office and its duties.